Aprea Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 25, 2025.
| | ||
|---|---|---|
| Aprea Therapeutics, Inc. | ||
| | | |
| | By | /s/ OREN GILAD |
| | | Oren Gilad, Ph.D. |
| | | President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Oren Gilad and John Hamill, as his or her attorney-in-fact, with the power of substitution, for each of them in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said attorney-in-facts, or their substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Signature | Title | Date | ||
|---|---|---|---|---|
| | | | | |
| /s/ OREN GILAD | | Chief Executive Officer and President (Principal Executive Officer) | | March 25, 2025 |
| Oren Gilad, Ph.D. | | | ||
| | | | | |
| /s/ JOHN P. HAMILL | | Chief Financial Officer (Principal Financial and Accounting Officer) | | March 25, 2025 |
| John P. Hamill | | | ||
| | | | | |
| /s/ JEAN-PIERRE BIZZARI | | Director | | March 25, 2025 |
| Jean-Pierre Bizzari, M.D. | | | | |
| | | | | |
| /s/ MARC DUEY | | Director | | March 25, 2025 |
| Marc Duey | | | ||
| | | | | |
| /s/ MICHAEL GRISSINGER | | Director | | March 25, 2025 |
| Michael Grissinger | | | ||
| | | | | |
| /s/ GABRIELA GRUIA | | Director | | March 25, 2025 |
| Gabriela Gruia, M.D. | | | | |
| | | | | |
| /s/ JOHN B. HENNEMAN, III | | Director | | March 25, 2025 |
| John B. Henneman, III. | | | ||
| | | | | |
| /s/ RIFAT PAMUKCU. | | Director | | March 25, 2025 |
| Rifat Pamukcu, M.D. | | | ||
| | | | | |
| /s/ RICHARD PETERS | | Director | | March 25, 2025 |
| Richard Peters, M.D., Ph.D. | | | ||
| | | | | |
| /s/ BERND R. SEIZINGER | | Director | | March 25, 2025 |
| Bernd R. Seizinger, M.D., Ph.D. | | | ||
| | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.